eXoZymes Inc..
EXOZ.US | Research and experimental development on natural sciences and engineering
I am unable to provide a company description or ISIC classification for "eXoZymes Inc. (EXOZ.US)" because I do not have enough information about the company's activities. To accurately classify the company, I need details about its products, services, and industry focus. For example, is it involved ...Show More
Better Health for All
0
eXoZymes' core business is developing enzymes and compounds, such as N-trans-caffeoyltyramine (NCT) and cannabinoid-inspired molecules, for therapeutic and nutraceutical applications.
1
These target significant health issues including obesity, type-2 diabetes, fatty liver disease (NAFLD/MASLD, MASH), and inflammatory bowel disorders.
2
The company's mission includes transforming the world through accessible solutions, with a roadmap to reduce cannabinoid production costs from $25,000-$50,000 per kilogram to under $1,000.
3
The company's products target conditions like MASLD, which impacts over 30% of the global population and over 100 million people in the US, and IBD, affecting over 4.5 million individuals globally.
4
The company includes a Safe Harbor statement in press releases regarding forward-looking statements and advises readers to consider risks and uncertainties described in SEC filings.
5
eXoZymes has received $16 million in federal grants and $5.9 million in private investment, along with a $2 million grant from the DOD’s BioMADE initiative and $250,000 in non-dilutive funding from Shell’s GameChanger Accelerator Program.
6
The company's exozyme-based process can replace toxic petrochemical processes with sustainable biosolutions.
7
The company leverages AI to generate and analyze extensive experimental datasets for optimizing its exozyme platform.
8
Since 2022, eXoZymes Inc. has held a bulk manufacturer license for the Schedule 1 controlled substance Tetrahydrocannabinol (THC), which has addiction potential.
9
The company plans for IND-enabling studies, and its developed compounds will be subject to the FDA approval process, requiring extensive clinical trials.
10
Fair Money & Economic Opportunity
0
eXoZymes Inc. is a biomanufacturing company focused on engineering advanced enzymes for sustainable bioproduction.
1
, not a financial institution. The provided articles do not contain any specific, concrete data points related to financial services, lending, or consumer finance metrics such as underserved client share, pricing fairness for financial products, exploitative fee exposure, financial inclusion initiatives, customer financial data accessibility, fair lending compliance, wealth-building outcomes for financial customers, profit reinvestment in community finance, financial literacy initiatives, customer debt burden ratios, geographic inclusion for banking services, or product simplicity for financial products. Therefore, no KPIs under the 'Fair Money & Economic Opportunity' value can be scored based on the evidence provided.
Fair Pay & Worker Respect
0
No specific, quantitative data points for EXOZ.US were found in the provided articles for any of the Fair Pay & Worker Respect KPIs.
1
The articles either discuss general industry trends, provide data for other companies, or are not relevant to EXOZ.US.
Fair Trade & Ethical Sourcing
0
No specific, concrete evidence regarding EXOZ.US's fair trade and ethical sourcing practices was found across the provided articles.
1
All articles either explicitly stated a lack of data specific to the company or were general discussions not relevant to the requested metrics.
2
Honest & Fair Business
0
No evidence available to assess eXoZymes Inc. on Honest & Fair Business.
Kind to Animals
0
No evidence available to assess eXoZymes Inc. on Kind to Animals.
No War, No Weapons
0
No evidence was found in the provided articles that directly pertains to EXOZ.US (eXoZymes Inc.) and the ethical value of "No War, No Weapons." The articles discuss general dual-use technology trends, EU export control regulations, and conflict minerals policies for other companies (Gentex, Memsic, D-Wave Quantum Inc.).
1
Articles referencing "Exosome Diagnostics" are not applicable as this is a distinct entity from EXOZ.US.
Planet-Friendly Business
0
No specific, quantifiable data points related to environmental performance, sustainability targets, or climate-friendly business practices for EXOZ.US were found in the provided articles. The articles explicitly state that data for all relevant KPIs is either 'not available' or 'no data provided'.
1
Respect for Cultures & Communities
0
No evidence available to assess eXoZymes Inc. on Respect for Cultures & Communities.
Safe & Smart Tech
0
No specific, concrete evidence was found in the provided articles to assess eXoZymes Inc. against any of the Key Performance Indicators for the 'Safe & Smart Tech' ethical value. The articles discuss the company's use of artificial intelligence for enzyme design and biomanufacturing breakthroughs, but do not provide information on data breaches, cybersecurity investments, privacy certifications, employee training, encryption, AI ethics governance, audit practices, algorithmic transparency, unauthorized data use, user data control, authentication security, vulnerability management, bug bounty programs, privacy by design, security testing, data minimization, regulatory compliance, algorithmic harm remediation, or digital rights advocacy.
1
Zero Waste & Sustainable Products
-50
eXoZymes Inc. has implemented "zero-waste processes for synthesizing high-purity compounds," indicating circular design considerations in some product lines.
1
The company's technology aims to replace toxic petrochemical processes with sustainable biosolutions, and it has received grants from the Department of Energy for sustainable aviation fuel programs, demonstrating waste reduction initiatives.
2
eXoZymes' technology is presented as a solution to problems with traditional cell-based methods that can involve toxic chemicals, suggesting some reduction initiatives for hazardous waste.
3
The company has quantitative waste reduction targets, specifically a "90% reduction in development timelines" for its processes.
4